oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalatio
Phase 1
- Conditions
- Breast cancer
- Registration Number
- JPRN-C000000429
- Lead Sponsor
- Outpatient Oncology Unit Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Infection, Fever = or > 38C Serious comorbidity Interstitial pneumonitis/fibrosis Peripheral neuropathy/edema Positive HBsAg Prior use of Anthracycline Decision by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) in oral CEF chemotherapy with intra-patient dose escalation
- Secondary Outcome Measures
Name Time Method Disease free survival time Adverse events graded by CTC